Amplifiers

Applied DNA CEO Discusses Relevance of DNA-based Cotton Traceability as Enabler of Ethical and Responsible Textile Manufacturing on BBC Business Daily

Retrieved on: 
Thursday, April 8, 2021
Biotechnology, Manufacturing, Other Health, Health, General Health, Pharmaceutical, Oncology, Other Science, Research, Textiles, Science, Branches of biology, Biology, Molecular biology, Natural sciences, Biotechnology, Laboratory techniques, DNA, Amplifiers, Cotton, Polymerase chain reaction, Gossypium barbadense, DNA sequencing

To date, CertainT has ensured the authenticity of approximately 300 million pounds of North American Pima and Upland cotton and has been deployed to secure Egyptian and Australian cotton.

Key Points: 
  • To date, CertainT has ensured the authenticity of approximately 300 million pounds of North American Pima and Upland cotton and has been deployed to secure Egyptian and Australian cotton.
  • CertainT begins by authenticating the fiber content in cotton to confirm its origin.
  • The platform then employs a unique molecular identifier produced by the Companys LinearDNA platform to mark cotton fibers in bulk.
  • Applied DNA is commercializing LinearDNA, its proprietary, large-scale polymerase chain reaction (PCR)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

Hologic to Acquire Mobidiag, Innovator in Near-Patient, Acute Care Diagnostic Testing, for Approximately $795 Million

Retrieved on: 
Thursday, April 8, 2021
Technology, Medical devices, Women, Software, Biotechnology, Health, Consumer, General Health, Data management, Articles, Life sciences, Branches of biology, Infectious diseases, Amplifiers, Biotechnology, Molecular biology, Polymerase chain reaction, Respiratory tract infection, Antimicrobial resistance, Infection

This includes a cash payment of approximately $714 million (600 million) for Mobidiags equity, and net debt of approximately $81 million.

Key Points: 
  • This includes a cash payment of approximately $714 million (600 million) for Mobidiags equity, and net debt of approximately $81 million.
  • Mobidiag develops and markets PCR (polymerase chain reaction)-based tests for acute care conditions such as gastrointestinal and respiratory infections, antimicrobial resistance management, and healthcare associated infections.
  • The Amplidiag and Novodiag platforms are automated instruments that deliver rapid turnaround times ranging from 50 minutes to two hours.
  • Mobidiag generated approximately $42 million (35 million) of revenue in calendar 2020.

Collection Sites Makes Affordable FDA EUA Approved COVID-19 At-Home Testing Available Nationwide

Retrieved on: 
Thursday, April 8, 2021
Articles, Life sciences, Branches of biology, Biotechnology, Laboratory techniques, Molecular biology, Polymerase chain reaction, Amplifiers, Clinical Laboratory Improvement Amendments, COVID-19, Reverse transcription polymerase chain reaction, Development of COVID-19 tests

The at-home test kits are available for purchase without a prescription by individuals through nationwide retail partners and by schools and businesses directly through the Collection Sites website.

Key Points: 
  • The at-home test kits are available for purchase without a prescription by individuals through nationwide retail partners and by schools and businesses directly through the Collection Sites website.
  • Collection Sites test kits are developed by a leading infectious disease laboratory and are based on the FDA EUA authorized SARS-CoV-2 RT-PCR assay.
  • Collection Sites expert lab processing and testing fee of $89.99 can be covered by health insurance or credit card.
  • The company provides pop-up COVID-19 lab testing services, business-focused testing services, and at-home testing services, powered by CLIA-licensed laboratories.

CareDx Announces New HLA Typing Service Offering for Research Purposes

Retrieved on: 
Thursday, April 8, 2021
Branches of biology, Biology, Life sciences, Biotechnology, Stem cells, Amplifiers, Molecular biology, Polymerase chain reaction, Cell therapy

The CareDx HLA typing service powered by AlloSeq Tx17 enables best-in-class research by using innovative hybrid-capture technology with the highest level of resolution, no long-range PCR inefficiencies, and a fast turnaround time.

Key Points: 
  • The CareDx HLA typing service powered by AlloSeq Tx17 enables best-in-class research by using innovative hybrid-capture technology with the highest level of resolution, no long-range PCR inefficiencies, and a fast turnaround time.
  • CareDxs HLA typing service in Stockholm has been engaged by one of the top 10 global pharmaceutical companies in the world, providing initial testing results in the first quarter of 2021.
  • This is an exciting time for CareDx we are not only expanding our capabilities but also investing in our global team to provide a first ever CareDx testing service outside the United States, said Alexander Johnson, SVP, Products, Cell Therapy and Business Development, CareDx.
  • This expansion allows us to partner with those at the forefront of drug development research and support improved care for even more patients around the world.

Leading diagnostics laboratory in the Caribbean selects Molecular Biology Systems's NextGenPCR for SARS-CoV-2 testing

Retrieved on: 
Wednesday, April 7, 2021
Molecular biology, Laboratory techniques, Biotechnology, Natural sciences, Biology, Life sciences, Polymerase chain reaction, Amplifiers, Reverse transcription polymerase chain reaction

FREDERICK, Md., April 7, 2021 /PRNewswire-PRWeb/ -- Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has announced that Aruba's Laboratorio di Servicio (LdS) has validated and implemented NextGenPCR for SARS-CoV-2 testing.

Key Points: 
  • FREDERICK, Md., April 7, 2021 /PRNewswire-PRWeb/ -- Dutch biotechnology company, Molecular Biology Systems, B.V. (MBS) has announced that Aruba's Laboratorio di Servicio (LdS) has validated and implemented NextGenPCR for SARS-CoV-2 testing.
  • "Last January, our lab Laboratorio di Servicio implemented the MBS' NextGenPCR solution for CoV2 screening, on Aruba."
  • "So, Laboratorio di Servicio is just one example of how NextGenPCR has delivered higher throughput by reducing time spent on RT-PCR."
  • Molecular Biology Systems, B.V., founded in 2015, is a life sciences solutions company based in Netherlands.

Applied DNA and Northwell Health Establish SARS-CoV-2 Mutation and Variant Tracking Program

Retrieved on: 
Wednesday, April 7, 2021
Research, Pharmaceutical, Oncology, Infectious diseases, Hospitals, Clinical trials, Science, Biotechnology, Stem cells, FDA, Other Science, Health, Branches of biology, Biology, Molecular biology, Natural sciences, Biotechnology, Laboratory techniques, Polymerase chain reaction, Amplifiers, Polymerase, DNA sequencing, Northwell Health, Applied DNA Sciences

Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and Northwell Health (Northwell) today announced their entry into a pro bono Material Transfer Agreement (MTA) that establishes a real-time surveillance program for the tracking and identification of SARS-CoV-2 mutations and variants of concern (VoCs) in Northwells COVID-positive specimens (the Program).

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (Applied DNA or the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, and Northwell Health (Northwell) today announced their entry into a pro bono Material Transfer Agreement (MTA) that establishes a real-time surveillance program for the tracking and identification of SARS-CoV-2 mutations and variants of concern (VoCs) in Northwells COVID-positive specimens (the Program).
  • The Program also provides valuable SARS-CoV-2 mutation data to support the continued validation of the Companys SGS Mutation Panel.
  • Northwell Health is New York States largest health care provider and private employer, with 23 hospitals, 830 outpatient facilities and more than 16,600 affiliated physicians.
  • Applied DNA is commercializing LinearDNA, its proprietary, large-scale polymerase chain reaction (PCR)-based manufacturing platform that allows for the large-scale production of specific DNA sequences.

Biomeme to Open New Headquarters at Netrality’s 401 North Broad

Retrieved on: 
Thursday, April 1, 2021
Natural sciences, Laboratory techniques, Chemistry, Physical sciences, Biotechnology, Amplifiers, Hoffmann-La Roche, Molecular biology, Polymerase chain reaction, Assay, Broad Street

PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- Netrality Data Centers announced today that Biomeme, Inc. , a leading developer and manufacturer of portable, real-time polymerase chain reaction (PCR) testing solutions, has selected Netralitys 401 North Broad Street for its new corporate headquarters.

Key Points: 
  • PHILADELPHIA, April 01, 2021 (GLOBE NEWSWIRE) -- Netrality Data Centers announced today that Biomeme, Inc. , a leading developer and manufacturer of portable, real-time polymerase chain reaction (PCR) testing solutions, has selected Netralitys 401 North Broad Street for its new corporate headquarters.
  • Situated in Philadelphias growing North Broad Street corridor, the 44,000 square foot space will house Biomemes laboratory, testing, manufacturing, fulfillment and office operations.
  • Netralitys 401 North Broad is the ideal home for our new headquarters.
  • Perelman also explained that Biomeme's expansion of device and assay manufacturing capacity at 401 North Broad will be enabled by the Commonwealth of Pennsylvania's Redevelopment Assistance Capital Program (RACP) grant of Three Million Dollars.

Applied DNA Appoints Clay Shorrock as Chief Legal Officer and Executive Director of Business Development

Retrieved on: 
Thursday, April 1, 2021
Other Health, Research, General Health, Professional services, Pharmaceutical, Oncology, Other Professional Services, Science, Legal, Biotechnology, Other Science, Health, Molecular biology, Biology, Branches of biology, Life sciences, Biotechnology, Laboratory techniques, Amplifiers, Hoffmann-La Roche, Polymerase chain reaction, Applied DNA Sciences

Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that Clay Shorrock, J.D., has rejoined the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Executive Director, Business Development.

Key Points: 
  • Applied DNA Sciences, Inc. (NASDAQ: APDN) (the Company), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that Clay Shorrock, J.D., has rejoined the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Executive Director, Business Development.
  • In this newly created role, Mr. Shorrock will lead Applied DNAs legal, regulatory, IP, and business development functions.
  • We look forward to his contributions to position Applied DNA for future success and shape sustained growth.
  • Mr. Shorrock served as in-house general and IP counsel to Applied DNA from 2016 through 2019, and thereafter as outside general and IP counsel.

Recent Surge of Cases Reiterates the Need for Accurate Diagnostics

Retrieved on: 
Wednesday, March 31, 2021
Biotechnology, Biology, Articles, Laboratory techniques, Molecular biology, Natural sciences, Amplifiers, Hoffmann-La Roche, Polymerase chain reaction

The increase in numbers further proves that mass scale testing is still a crucial component in the fight against the pandemic.

Key Points: 
  • The increase in numbers further proves that mass scale testing is still a crucial component in the fight against the pandemic.
  • Todos intends to make GeneFinder Plus the primary kit used for distribution in its fully integrated and automated COVID-19 PCR testing lab solutions.
  • You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions.
  • Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed.

Recent Surge of Cases Reiterates the Need for Accurate Diagnostics

Retrieved on: 
Wednesday, March 31, 2021
Biotechnology, Biology, Articles, Laboratory techniques, Molecular biology, Natural sciences, Amplifiers, Hoffmann-La Roche, Polymerase chain reaction

The increase in numbers further proves that mass scale testing is still a crucial component in the fight against the pandemic.

Key Points: 
  • The increase in numbers further proves that mass scale testing is still a crucial component in the fight against the pandemic.
  • Todos intends to make GeneFinder Plus the primary kit used for distribution in its fully integrated and automated COVID-19 PCR testing lab solutions.
  • You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions.
  • Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed.